All Stories

  1. Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d’Ivoire, West Africa: A cross-sectional study
  2. Appropriateness of Ticagrelor Use at Initiation: A Population-Based Cohort Study
  3. Risk of pulmonary toxicity of bleomycin and filgrastim
  4. Measuring adherence to oral antidiabetic multi-drug treatment: Comparative validity of prescription claims-based adherence measures against hospitalization
  5. Patients’ beliefs about adherence to oral antidiabetic treatment: a qualitative study [Corrigendum]
  6. Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users?
  7. The impact of incident depression on medication adherence in patients with type 2 diabetes
  8. Factors associated with adherence to asthma treatment with inhaled corticosteroids: A cross-sectional exploratory study
  9. Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure
  10. Persistence and compliance with newly initiated antihypertensive drug treatment in patients with chronic kidney disease
  11. Psychosocial factors associated with adherence to non-insulin antidiabetes treatments
  12. Patients’ beliefs about adherence to oral antidiabetic treatment: a qualitative study
  13. Important Treatment Gaps in Vascular Protection for the Elderly After Type 2 Diabetes Therapy Initiation
  14. Community pharmacy loyalty among individuals with schizophrenia
  15. Spatio-temporal clustering of the incidence of schizophrenia in Quebec, Canada from 2004 to 2007
  16. Hypoglycemia-Related Emergency Department Visits and Hypoglycemia-Related Hospitalizations among New Users of Antidiabetes Treatments
  17. Difficulty adhering to antidiabetic treatment: Factors associated with persistence and compliance
  18. Does elapsed time between first diagnosis of schizophrenia and migration between health territories vary by place of residence? A survival analysis approach
  19. Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?
  20. Treatment prevalence and incidence of schizophrenia in Quebec using a population health services perspective: different algorithms, different estimates
  21. Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients—A Population-Based Study
  22. Adherence to vascular protection drugs in diabetic patients in Quebec: a population-based analysis
  23. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis
  24. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients
  25. Association between age and the initiation of antihypertensive, lipid lowering and antiplateletet medications in elderly individuals newly treated with antidiabetic drugs
  26. Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs
  27. Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents
  28. The Natural History of Insomnia
  29. The benefit of aspirin therapy in type 2 diabetes: What is the evidence?
  30. Underuse of cardioprotective treatment by the elderly with type 2 diabetes
  31. Factors Associated with Long-Term Benzodiazepine Use Among Elderly Women and Men in Quebec
  32. Social context, the struggle with uncertainty, and subjective risk as meaning-rich constructs for explaining HBP noncompliance
  33. Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes
  34. Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers
  35. Effect of drug utilization reviews on the quality of in-hospital prescribing: a quasi-experimental study
  36. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors
  37. Health-related quality of life in hypertension: impact of a pharmacy intervention programme
  38. Spatial variation in the management and outcomes of acute coronary syndrome
  39. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec
  40. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study
  41. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine
  42. Potentially inappropriate prescriptions for older patients in long-term care
  43. The societal value of universal childhood vaccination
  44. Pharmacist Intervention Program for Control of Hypertension
  45. A Pharmacy-Based Health Promotion Programme in Hypertension
  46. Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease
  47. Determinants of discontinuation of new courses of antihypertensive medications
  48. Non-Compliance with Drug Treatment and Reading Difficulties with Regard to Prescription Labelling among Seniors
  49. Tolerability of antihypertensive drugs in a community-based setting
  50. Ambulatory Use of Inhaled β2-Agonists for the Treatment of Asthma in Quebec